Introduction

Ruxotor 10 mg (Ruxolitinib Phosphate) is an advanced oral therapy designed for patients with certain blood cancers and inflammatory conditions. Manufactured by Everest Pharmaceuticals Ltd. and supplied worldwide by Onco Solution, Ruxotor belongs to a class of medicines known as Janus kinase (JAK) inhibitors.

Ruxolitinib, the active ingredient in Ruxotor, has transformed the management of myelofibrosis, polycythemia vera (PV), and graft-versus-host disease (GVHD). By targeting abnormal JAK signaling pathways, it helps control disease progression, improve symptoms, and enhance overall quality of life for patients.

Key Benefits of Ruxotor 10 mg

• Effective JAK1/JAK2 Inhibition – Ruxolitinib blocks overactive signaling pathways that drive abnormal blood cell growth.
• Symptom Relief – Reduces spleen enlargement, fatigue, night sweats, itching, and bone pain.
• Improved Blood Counts – Particularly beneficial in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
• Versatile Applications – Used in both hematologic malignancies and inflammatory disorders.
• Oral Tablet Formulation – Convenient daily dosing from home under medical supervision.

Indications

Ruxotor 10 mg is indicated for the treatment of:

1. Myelofibrosis (MF)
   • Includes primary myelofibrosis, post-polycythemia vera MF, and post-essential thrombocythemia MF.
   • Helps reduce splenomegaly and control disease-related symptoms.
2. Polycythemia Vera (PV)
   • For adult patients who are resistant to or intolerant of hydroxyurea.
   • Assists in controlling hematocrit levels and reducing the need for phlebotomy.
3. Graft-Versus-Host Disease (GVHD)
   • Approved for steroid-refractory acute and chronic GVHD in adult and pediatric patients (≥12 years).

Dosage and Administration

• Initial Dose:
  • Myelofibrosis: Typically 15–20 mg twice daily depending on platelet counts.
  • Polycythemia Vera: 10 mg twice daily.
  • GVHD: 5–10 mg twice daily, adjusted per clinical response.
• Adjustments:
  • Dose modifications required in case of thrombocytopenia, anemia, neutropenia, or renal/hepatic impairment.
• Administration:
  • Take orally, with or without food, at the same time each day.
  • Tablets should be swallowed whole with water.

Always follow the dosing regimen prescribed by a qualified oncologist or hematologist.

Pharmacology

• Class: Janus Kinase (JAK) inhibitor.
• Mechanism of Action: Ruxolitinib selectively inhibits JAK1 and JAK2 enzymes. These kinases regulate cytokine signaling responsible for blood cell production and immune system activity. In conditions like myelofibrosis and PV, JAK pathways are overactive, leading to uncontrolled cell growth. Ruxotor normalizes this activity, improving blood counts and reducing symptoms.
• Pharmacokinetics:
  • Absorption: Rapidly absorbed, peak plasma concentration in 1–2 hours.
  • Metabolism: Primarily hepatic (CYP3A4 enzyme system).
  • Half-life: Approximately 3 hours.
  • Excretion: Through urine and feces.

Contraindications

Ruxotor should not be used in patients with:

• Known hypersensitivity to Ruxolitinib or any component of the formulation.
• Severe uncontrolled infections.
• Pregnancy or breastfeeding, unless the benefits outweigh risks.

Drug Interactions

• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) – may increase drug concentration, requiring dose reduction.
• CYP3A4 inducers (rifampin, carbamazepine) – may reduce effectiveness.
• Anticoagulants/antiplatelets – increased risk of bleeding.
• Immunosuppressants – additive risk of infections.

Possible Side Effects

Like other targeted therapies, Ruxotor may cause side effects. The most common include:

• Hematologic: Anemia, thrombocytopenia, neutropenia.
• Infections: Increased susceptibility to bacterial, viral, and fungal infections.
• Metabolic: Weight gain, hypercholesterolemia.
• Gastrointestinal: Diarrhea, nausea, abdominal pain.
• Other: Headache, dizziness, bruising, elevated liver enzymes.

Serious but rare risks include tuberculosis reactivation, herpes zoster, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

• Regular Blood Tests: CBC monitoring is mandatory to adjust dosage.
• Infection Risk: Patients should be screened for tuberculosis and hepatitis before initiation.
• Skin Cancer: Non-melanoma skin cancers have been reported; regular dermatological exams recommended.
• Pregnancy: Not advised; effective contraception required during and after therapy.
• Vaccinations: Live vaccines should be avoided during treatment.

Use in Special Populations

• Elderly: Generally well tolerated but may require dose adjustments due to comorbidities.
• Renal Impairment: Lower starting doses recommended.
• Hepatic Impairment: Caution required; dose modification may be necessary.
• Pediatric Use: Approved for GVHD in children ≥12 years under specialist supervision.

Overdose

Symptoms may include severe hematological toxicity, dizziness, and increased risk of infections. Immediate supportive medical care is required in overdose cases.

Storage Guidelines

• Store below 30°C.
• Protect from moisture and direct sunlight.
• Keep out of reach of children.

Manufacturer – Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a Bangladesh-based global pharmaceutical company known for producing high-quality, affordable medicines. The company adheres to WHO GMP and ISO-certified standards, ensuring that products like Ruxotor 10 mg meet international safety and efficacy benchmarks. Everest is recognized for its commitment to innovation in oncology and hematology therapeutics.

Supplier Profile – Onco Solution

Onco Solution is a leading oncology medicine supplier, providing global access to life-saving cancer and hematology treatments. With a wide product portfolio, strong logistics support, and a reputation for reliability, Onco Solution ensures that patients and healthcare providers can access essential therapies like Ruxotor 10 mg (Ruxolitinib Phosphate) with ease and trust.

Conclusion

Ruxotor 10 mg (Ruxolitinib Phosphate) is a groundbreaking therapy in the management of myeloproliferative disorders such as myelofibrosis, polycythemia vera, and graft-versus-host disease. By targeting the JAK-STAT signaling pathway, it addresses both the underlying disease mechanism and its associated symptoms.

Manufactured by Everest Pharmaceuticals Ltd. and supplied worldwide by Onco Solution, Ruxotor offers patients a reliable, research-backed, and effective treatment option. With proven benefits, patient-friendly oral dosing, and global accessibility, it continues to improve the lives of patients battling challenging hematological conditions.